Propanc Biopharma board changes: Kenyon retires, Brandt appointed

Propanc Biopharma, Inc.

Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.
Dr. Ralf Brandt appointed to Board same day; 30+ yrs pharma/oncology experience.
Brandt to receive $45,000 annual compensation under Director Agreement.
Brandt has served as CEO of vivoPharm and held exec roles at Novartis and Bionomics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.